Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217269 · ClinicalTrials.gov registry record · NA
The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 1,548
- Enrollment target
NCT00217269 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 1,548 participants.
The verdict
NCT00217269, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,548 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries with a reference vessel diameter (RVD) of 2.5-3.5 mm.
Interventions
- DEVICE Coronary Artery Stenting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,548 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217269
The ClinicalTrials.gov registry entry for NCT00217269 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,548 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Coronary Artery Stenting is the first listed.
NCT00217269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217269 about?
NCT00217269 is a clinical study titled "The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions". The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries with a reference vessel diamete...
What is the current status of trial NCT00217269?
This trial is currently completed. It is a NA study. The enrollment target is 1,548 participants. The study started on 2005-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00217269?
The interventions under investigation include: Coronary Artery Stenting (DEVICE).
Who is sponsoring clinical trial NCT00217269?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.